The invention relates to a nelarabine injection, which is characterized by consisting of nelarabine, EDTA or EDTA salt,
sodium chloride, and water for injection, wherein the nelarabine accounts for 0.25 to 0.625 percent of the total weight of the injection, the EDTA or the EDTA salt accounts for 0.001 to 0.01 percent of the total weight of the injection, the content of the
sodium chloride is 0 or the
dose is used for regulating the
osmotic pressure, and the balance is the water for injection. The preparing process comprises the following steps: taking 80 percent of the water for injection, adding raw supplementary materials into the water for injection, stirring the mixture to fully dissolve the raw supplementary materials and mixing the mixture evenly, adjusting the pH value, adding 0.02 percent of needle
activated carbon into the mixture, keeping the
water temperature at 70 DEG C, stirring the mixture for 30 minutes, filtering the mixture to remove the
activated carbon when the mixture is hot, cooling the mixture to
room temperature, measuring the contents and the pH value of the solution, adding the water for injection with full
dose into the solution, mixing the mixture evenly, filtering the mixture through 0.22 mu m of
microfiltration membrane until the mixture is clear, packaging the filtrate into infusion bottles after intermediates are measured to be qualified, plugging the bottles, and rolling the mouths of the bottoms to obtain the nelarabine injection after
hot pressing sterilization.